Medication-related costs of rhinitis in Australia: a NostraData cross-sectional study of pharmacy purchases

Pete Smith, David Price, Richard Harvey, Andrew Simon Carney, Vicky Kritikos, Sinthia Z Bosnic-Anticevich, Louise Christian, Alice M S Durieux

Research output: Contribution to journalArticle

5 Citations (Scopus)
3 Downloads (Pure)

Abstract

Purpose: There is a relative paucity of research regarding medication expenditure associated with multiple-therapy use for rhinitis in Australia. To describe 1) the nature and extent of multiple-therapy use for rhinitis in Australia using data on therapies purchased with prescription or over-the-counter (OTC) and 2) additional costs incurred by multiple-therapy use compared with intranasal corticosteroid (INCS) therapy alone.
Patients and methods: A retrospective observational study was carried out using a database containing anonymous pharmacy transaction data available from 20% of pharmacies in Australia that links doctor prescriptions and OTC purchase information. Pharmacy purchases of at least one prescription or OTC rhinitis treatment, with or without additional asthma/chronic obstructive pulmonary disease (COPD) therapy, by patients during 2013 and 2014 were assessed.
Results: In total, 4,247,193 prescription and OTC rhinitis treatments were purchased from 909 pharmacies over 24 months. The majority of rhinitis therapy transactions were single-therapy purchases without additional asthma/COPD therapy. Of the single therapies purchased, 73% were oral antihistamines (OAHs) and 15% were INCS therapy. Dual-therapy purchases of INCSs and OAHs accounted for 40% of multiple-therapy purchases. Patients frequently purchased OAHs, nonsteroidal nasal sprays, and eye drops for allergic conjunctivitis alongside INCSs, resulting in higher financial costs (up to AU$21 per treatment episode) compared with INCS monotherapy.
Conclusion: This study highlighted the significant burden posed on community pharmacy to address the needs of people with rhinitis symptoms, and the failure to translate the evidence that INCSs are the most effective monotherapy for moderate to severe and/or persistent rhinitis into clinical practice in light of the lack of evidence supporting combination of INCS and OAH therapy. Health care professional engagement, especially at the pharmacy level, will be extremely important if we wish to ensure that the purchase of rhinitis treatment is in accordance with guidelines and that their use is optimal.
Original languageEnglish
Pages (from-to)153-161
Number of pages9
JournalJournal of Asthma and Allergy
Volume2017
Issue number10
DOIs
Publication statusPublished - 9 May 2017

Fingerprint

Rhinitis
Cross-Sectional Studies
Costs and Cost Analysis
Therapeutics
Histamine Antagonists
Prescriptions
Pharmacies
Adrenal Cortex Hormones
Chronic Obstructive Pulmonary Disease
Asthma
Allergic Conjunctivitis
Nasal Sprays
Ophthalmic Solutions
Health Expenditures

Keywords

  • community pharmacy
  • intranasal corticosteroids
  • oral antihistamines
  • over-the-counter
  • prescription
  • rhinitis
  • therapy

Cite this

Smith, P., Price, D., Harvey, R., Carney, A. S., Kritikos, V., Bosnic-Anticevich, S. Z., ... Durieux, A. M. S. (2017). Medication-related costs of rhinitis in Australia: a NostraData cross-sectional study of pharmacy purchases. Journal of Asthma and Allergy, 2017(10), 153-161. https://doi.org/10.2147/JAA.S128431

Medication-related costs of rhinitis in Australia : a NostraData cross-sectional study of pharmacy purchases. / Smith, Pete; Price, David; Harvey, Richard ; Carney, Andrew Simon ; Kritikos, Vicky; Bosnic-Anticevich, Sinthia Z ; Christian, Louise ; Durieux, Alice M S.

In: Journal of Asthma and Allergy, Vol. 2017, No. 10, 09.05.2017, p. 153-161.

Research output: Contribution to journalArticle

Smith, P, Price, D, Harvey, R, Carney, AS, Kritikos, V, Bosnic-Anticevich, SZ, Christian, L & Durieux, AMS 2017, 'Medication-related costs of rhinitis in Australia: a NostraData cross-sectional study of pharmacy purchases', Journal of Asthma and Allergy, vol. 2017, no. 10, pp. 153-161. https://doi.org/10.2147/JAA.S128431
Smith, Pete ; Price, David ; Harvey, Richard ; Carney, Andrew Simon ; Kritikos, Vicky ; Bosnic-Anticevich, Sinthia Z ; Christian, Louise ; Durieux, Alice M S. / Medication-related costs of rhinitis in Australia : a NostraData cross-sectional study of pharmacy purchases. In: Journal of Asthma and Allergy. 2017 ; Vol. 2017, No. 10. pp. 153-161.
@article{b045546fa6c44d6abd7f6fe9bc83e84b,
title = "Medication-related costs of rhinitis in Australia: a NostraData cross-sectional study of pharmacy purchases",
abstract = "Purpose: There is a relative paucity of research regarding medication expenditure associated with multiple-therapy use for rhinitis in Australia. To describe 1) the nature and extent of multiple-therapy use for rhinitis in Australia using data on therapies purchased with prescription or over-the-counter (OTC) and 2) additional costs incurred by multiple-therapy use compared with intranasal corticosteroid (INCS) therapy alone.Patients and methods: A retrospective observational study was carried out using a database containing anonymous pharmacy transaction data available from 20{\%} of pharmacies in Australia that links doctor prescriptions and OTC purchase information. Pharmacy purchases of at least one prescription or OTC rhinitis treatment, with or without additional asthma/chronic obstructive pulmonary disease (COPD) therapy, by patients during 2013 and 2014 were assessed.Results: In total, 4,247,193 prescription and OTC rhinitis treatments were purchased from 909 pharmacies over 24 months. The majority of rhinitis therapy transactions were single-therapy purchases without additional asthma/COPD therapy. Of the single therapies purchased, 73{\%} were oral antihistamines (OAHs) and 15{\%} were INCS therapy. Dual-therapy purchases of INCSs and OAHs accounted for 40{\%} of multiple-therapy purchases. Patients frequently purchased OAHs, nonsteroidal nasal sprays, and eye drops for allergic conjunctivitis alongside INCSs, resulting in higher financial costs (up to AU$21 per treatment episode) compared with INCS monotherapy.Conclusion: This study highlighted the significant burden posed on community pharmacy to address the needs of people with rhinitis symptoms, and the failure to translate the evidence that INCSs are the most effective monotherapy for moderate to severe and/or persistent rhinitis into clinical practice in light of the lack of evidence supporting combination of INCS and OAH therapy. Health care professional engagement, especially at the pharmacy level, will be extremely important if we wish to ensure that the purchase of rhinitis treatment is in accordance with guidelines and that their use is optimal.",
keywords = "community pharmacy, intranasal corticosteroids, oral antihistamines, over-the-counter, prescription, rhinitis, therapy",
author = "Pete Smith and David Price and Richard Harvey and Carney, {Andrew Simon} and Vicky Kritikos and Bosnic-Anticevich, {Sinthia Z} and Louise Christian and Durieux, {Alice M S}",
year = "2017",
month = "5",
day = "9",
doi = "10.2147/JAA.S128431",
language = "English",
volume = "2017",
pages = "153--161",
journal = "Journal of Asthma and Allergy",
issn = "1178-6965",
publisher = "Dove Medical Press Ltd.",
number = "10",

}

TY - JOUR

T1 - Medication-related costs of rhinitis in Australia

T2 - a NostraData cross-sectional study of pharmacy purchases

AU - Smith, Pete

AU - Price, David

AU - Harvey, Richard

AU - Carney, Andrew Simon

AU - Kritikos, Vicky

AU - Bosnic-Anticevich, Sinthia Z

AU - Christian, Louise

AU - Durieux, Alice M S

PY - 2017/5/9

Y1 - 2017/5/9

N2 - Purpose: There is a relative paucity of research regarding medication expenditure associated with multiple-therapy use for rhinitis in Australia. To describe 1) the nature and extent of multiple-therapy use for rhinitis in Australia using data on therapies purchased with prescription or over-the-counter (OTC) and 2) additional costs incurred by multiple-therapy use compared with intranasal corticosteroid (INCS) therapy alone.Patients and methods: A retrospective observational study was carried out using a database containing anonymous pharmacy transaction data available from 20% of pharmacies in Australia that links doctor prescriptions and OTC purchase information. Pharmacy purchases of at least one prescription or OTC rhinitis treatment, with or without additional asthma/chronic obstructive pulmonary disease (COPD) therapy, by patients during 2013 and 2014 were assessed.Results: In total, 4,247,193 prescription and OTC rhinitis treatments were purchased from 909 pharmacies over 24 months. The majority of rhinitis therapy transactions were single-therapy purchases without additional asthma/COPD therapy. Of the single therapies purchased, 73% were oral antihistamines (OAHs) and 15% were INCS therapy. Dual-therapy purchases of INCSs and OAHs accounted for 40% of multiple-therapy purchases. Patients frequently purchased OAHs, nonsteroidal nasal sprays, and eye drops for allergic conjunctivitis alongside INCSs, resulting in higher financial costs (up to AU$21 per treatment episode) compared with INCS monotherapy.Conclusion: This study highlighted the significant burden posed on community pharmacy to address the needs of people with rhinitis symptoms, and the failure to translate the evidence that INCSs are the most effective monotherapy for moderate to severe and/or persistent rhinitis into clinical practice in light of the lack of evidence supporting combination of INCS and OAH therapy. Health care professional engagement, especially at the pharmacy level, will be extremely important if we wish to ensure that the purchase of rhinitis treatment is in accordance with guidelines and that their use is optimal.

AB - Purpose: There is a relative paucity of research regarding medication expenditure associated with multiple-therapy use for rhinitis in Australia. To describe 1) the nature and extent of multiple-therapy use for rhinitis in Australia using data on therapies purchased with prescription or over-the-counter (OTC) and 2) additional costs incurred by multiple-therapy use compared with intranasal corticosteroid (INCS) therapy alone.Patients and methods: A retrospective observational study was carried out using a database containing anonymous pharmacy transaction data available from 20% of pharmacies in Australia that links doctor prescriptions and OTC purchase information. Pharmacy purchases of at least one prescription or OTC rhinitis treatment, with or without additional asthma/chronic obstructive pulmonary disease (COPD) therapy, by patients during 2013 and 2014 were assessed.Results: In total, 4,247,193 prescription and OTC rhinitis treatments were purchased from 909 pharmacies over 24 months. The majority of rhinitis therapy transactions were single-therapy purchases without additional asthma/COPD therapy. Of the single therapies purchased, 73% were oral antihistamines (OAHs) and 15% were INCS therapy. Dual-therapy purchases of INCSs and OAHs accounted for 40% of multiple-therapy purchases. Patients frequently purchased OAHs, nonsteroidal nasal sprays, and eye drops for allergic conjunctivitis alongside INCSs, resulting in higher financial costs (up to AU$21 per treatment episode) compared with INCS monotherapy.Conclusion: This study highlighted the significant burden posed on community pharmacy to address the needs of people with rhinitis symptoms, and the failure to translate the evidence that INCSs are the most effective monotherapy for moderate to severe and/or persistent rhinitis into clinical practice in light of the lack of evidence supporting combination of INCS and OAH therapy. Health care professional engagement, especially at the pharmacy level, will be extremely important if we wish to ensure that the purchase of rhinitis treatment is in accordance with guidelines and that their use is optimal.

KW - community pharmacy

KW - intranasal corticosteroids

KW - oral antihistamines

KW - over-the-counter

KW - prescription

KW - rhinitis

KW - therapy

U2 - 10.2147/JAA.S128431

DO - 10.2147/JAA.S128431

M3 - Article

VL - 2017

SP - 153

EP - 161

JO - Journal of Asthma and Allergy

JF - Journal of Asthma and Allergy

SN - 1178-6965

IS - 10

ER -